09:19 ET - Baxter International has a little more than two weeks to figure out what to relay to investors about the extent to which tariffs will affect its business. The medical-products maker will have a conference call Feb. 20 to discuss its 4Q results. Its guidance for 2025 will garner more attention in the wake of broad tariffs that President Trump has levied against Mexico, Canada and China set to go into effect Tuesday. Baxter on Monday noted its 2025 adjusted operating margin view of 16.5% doesn't include any impact from such tariffs. The company added it's working to quantify the expected impact of such tariffs, as well as identify potential mitigation opportunities, and will provide an update on its 4Q call. Shares edge down 2.3% to $31.81 in premarket trading. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
February 03, 2025 09:19 ET (14:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。